Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JLP-1310 vs Metformin SR + Rosuvastatin in Healthy Volunteers
NCT02982798Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JLP-1310 in type 2 diabetes mellitus (T2DM) and hyperlipidemia, sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Jul 2017; status: completed.
02
Drugs
JLP-1310
03
Conditions
type 2 diabetes mellitus (T2DM)hyperlipidemia
Beyond the preview
Go deeper on NCT02982798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982798.